Lercanidipina Aurovitas (Lercanidipine Hydrochloride)

Lercanidipine is used to manage high blood pressure, acting on the vascular smooth‑muscle calcium channels that regulate tone.

• Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure.
• Isolated systolic hypertension: lowers elevated systolic readings, especially in older adults.
• General hypertension: helps achieve target blood pressure levels as part of antihypertensive therapy.

• Lercanidipine selectively inhibits L‑type calcium channels in vascular smooth muscle, decreasing calcium influx. This leads to relaxation of arterial smooth muscle, vasodilation, and a consequent reduction in peripheral vascular resistance, which lowers systemic blood pressure without significant effect on cardiac contractility.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: warm sensation with reddening of skin.
• Peripheral edema: swelling of ankles or feet.
• Dizziness: especially upon standing.
• Tiredness: general feeling of fatigue.
• Palpitations: awareness of heartbeat.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Angio‑edema: rapid swelling of face, lips, or throat.
• Hepatic dysfunction: abnormal liver enzymes.
• Allergic reactions: rash, itching, or anaphylaxis.
• Cardiac arrhythmias: irregular heart rhythms.
• Renal impairment: worsening kidney function.

Before initiating therapy, consider patient‑specific factors and monitor for potential risks.

• Pregnancy: safety not established; avoid unless clearly needed.
• Breastfeeding: unknown excretion; weigh benefits against risks.
• Liver disease: use with caution; dose adjustment may be required.
• Elderly: monitor for orthostatic hypotension and renal function.
• Drug interactions: review concomitant medications for additive blood‑pressure effects.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and risk of hypotension.
• Grapefruit juice: can elevate drug concentration leading to adverse effects.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (e.g., ACE inhibitors, diuretics): may cause additive blood‑pressure lowering.

• Simvastatin or other CYP3A4 substrates: may increase statin exposure, raising myopathy risk.
• Beta‑blockers: monitor for excessive bradycardia or hypotension.
• NSAIDs: may attenuate antihypertensive effect.
• Alcohol: can enhance vasodilatory effects, leading to dizziness.